Outpatient versus hospital care for blood cancer drug dose increases

This trial is testing whether patients with relapsed multiple myeloma can receive dose escalations of bispecific antibodies—like teclistamab, elranatamab, or talquetamab—safely as outpatients rather than staying in the hospital. The study will compare two groups: people who receive their dose increases at home (if it's safe and practical) and people who receive them in the hospital. Researchers will measure how each approach affects quality of life, side effects, and overall healthcare costs.

Currently, many patients with relapsed myeloma stay in the hospital while their medication dose is gradually increased to find the right level. This trial wants to know if it's possible and beneficial to do these dose increases in an outpatient setting—letting patients go home between treatments—which could improve quality of life and reduce healthcare expenses.